PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
1 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.
2 . The method according to claim 1 , wherein said antagonist is a small molecule antagonist.
3 . The method according to claim 1 , wherein said antagonist has formula (I)
or pharmaceutically acceptable salts thereof, wherein n is 0 or 1; m is 1, 2 or 3; R 1 is H, C 1 -C 3 alkyl, halogenated C 1 -C 3 alkyl or cyclopropyl; R 2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.
4 . The method according to claim 1 , wherein said PTGDR-1 antagonist is laropiprant.
5 . The method according to claim 1 , wherein said PTGDR-1 antagonist is used in combination with at least a PTGDR-2 antagonist.
6 . The method according to claim 5 , wherein said PTGDR-2 antagonist has formula (VIII)
wherein R1 is H, fluorine, methyl, methoxy, benzyloxy, or hydroxyl,
R2 is phenyl which is substituted by fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropyl, or methoxy, and
Y is 0 or 1,
or pharmaceutically acceptable salts thereof.
7 . The method according to claim 5 , wherein said PTGDR-2 antagonist is CAY10471 (TM30089).
8 . The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in a single pharmaceutical composition.
9 . The method according to claim 5 , wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.
10 . The method according to claim 1 , wherein said PTGDR-1 antagonist is a dual PTGDR-1/PTGDR-2 antagonist.
11 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.
12 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist as a combined preparation for simultaneous use, separate use, or use spread over time.
13 . A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.
14 . The method according to claim 1 , wherein the PTGDR-1 antagonist prevents basophil homing to secondary lymphoid organs.
15 . The method according to claim 1 , wherein the PTGDR-1 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares and/or organ damages.
16 . The method according to claim 11 , wherein said PTGDR-1 antagonist is a small molecule antagonist.
17 . The method according to claim 11 , wherein said PTGDR-1 antagonist is chosen from the groups consisting of compounds of formula (I):
and their pharmaceutically acceptable salts, wherein n is 0 or 1; m is 1, 2 or 3; R 1 is H, C 1 -C 3 alkyl, halogenated C 1 -C 3 alkyl or cyclopropyl; R 2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.
18 . The method according to claim 11 , wherein said PTGDR-1 antagonist is laropiprant.
19 . The method according to claim 11 , wherein said PTGDR-2 antagonist antagonist is chosen from the groups consisting of compounds of formula (VIII):
wherein R1 is H, fluorine, methyl, methoxy, benzyloxy, or hydroxyl,
R2 is phenyl which is substituted by fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropyl, or methoxy, and
Y is 0 or 1,
and their pharmaceutically acceptable salts.
20 . The method according to claim 11 , wherein said PTGDR-2 antagonist is CAY10471 (TM30089).